TickerTalks
Browse all tickers →
TickerTalks›$HTFL
HTHTFL

Heartflow, Inc. Common Stock

$HTFL·$4.2B·Medical - Healthcare Information Services·Healthcare
$49.83-0.2%YTD+69.8%1Y+44.7%
Price updated 6h ago·X counts updated 2d ago
HTHTFL
$HTFLHeartflow, Inc. Common Stock
$49.83-0.18%32 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $HTFL on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

32X posts · last 7 days
Sep 12Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $HTFL's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 77% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data7 posts analyzed · as of 2026-09-07

HeartFlow is a healthcare + AI bull's core position. Post-earnings ran +67% then revisited the 10-day and moved higher on volume, about to break recent highs. Clinical data shows adding FFR analysis reduces unnecessary invasive procedures in stable CAD, and traders are letting stops run rather than trimming.

Read what X is saying about $HTFL

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $HTFL — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-09-29

The move is getting stronger, with heavier trading behind it.

HeartFlow is up 70% year-to-date and 93% of its 52-week range on 48% Q2 revenue growth — the CEO sold $1.8M into the strength but the operational curve is intact.

HeartFlow is a $4.2B-cap coronary-artery-disease AI-diagnostics company whose FFR-based non-invasive imaging is showing strong commercial traction.

  • Up 70% year to date and 45% over the last twelve months, at 93% of its 52-week range, 25% above the 50-day and 59% above the 200-day moving average.
  • Q2 revenue $64M grew 48% year over year at 83% gross margin and -28% operating margin — a very SaaS-like margin structure with heavy investment for growth.
  • Q1 revenue $53M grew 41% year over year — the acceleration is durable.
  • Trailing P/E -30, price-to-sales 17 — priced for continued high-growth execution.
  • Three straight beats of 15-48% surprise magnitude — earnings execution is running ahead of expectations.
  • Twelve insider dispositions in the last month — including the CEO selling 38,900 shares for $1.8M and CFO Farquhar selling 35,010 shares — a real distribution pattern at the highs.
  • Beta 2.02 — high-beta name that can unwind quickly on a miss.

The November 11 print needs to hold revenue growth above 40% and show operating margin narrowing; the insider distribution says caution at these levels.

Agrees with X sentimentThe X sample flags the same post-earnings +67% move, the volume-supported break of highs, and the clinical-data support — that matches the tape, though the insider distribution the sample doesn't emphasize is worth watching.

What to watch: November 11 print — revenue growth staying above 40%, operating margin lifting toward -20%, and whether insider dispositions continue at scale.

On the calendar: 2026-11-11 — Q3 earnings

insider selling clusterhigh beta

Read the AI verdict on $HTFL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

AI-driven cardiac diagnostic platform creating 3D coronary artery models from CT scans to guide treatment without invasive testing.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $HTFL.

Medical - Healthcare Information Services · Healthcare

No material change from last week — AI-driven clinical workflow digitization and prior-authorization automation are the structural demand drivers.

What this means for $HTFL

Partial — AI-driven cardiac diagnostic platform creating 3D coronary artery models from CT scans to guide treatment without invasive testing.

Industry benchmark

10-name peer basket
+12.0%YTD
+6.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-29.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-23.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-34.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-1.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
17.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-42.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
80.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.07$-0.13+47.6%
Q1 2026May 14, 2026$-0.16$-0.19+14.7%
Q4 2025Mar 18, 2026$-0.12$-0.19+36.0%
Q3 2025Nov 12, 2025$-0.27$-0.20-35.0%
Next earningsWed, Nov 11·consensus EPS $-0.10

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$64.1M+47.6%83.0%-27.9%$-0.18$-10.5M
Q1 FY26$52.6M+41.3%80.2%-41.9%$-0.32$-32.0M
Q4 FY25$49.1M+40.5%79.5%-36.1%$-0.29$-12.5M
Q3 FY25$46.3M+40.5%76.5%-32.6%$-0.63$-4.2M

Forward consensus

5-year forecast · up to 8 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$248.9M$248.1M – $250.6M-$0.41-$0.45 – -$0.388
FY27$309.0M$300.8M – $314.1M-$0.26-$0.47 – -$0.158
FY28$371.2M$361.8M – $390.1M$0.07-$0.14 – $0.437
FY29$443.9M$435.6M – $453.8M$0.35$0.34 – $0.363
FY30$515.9M$506.2M – $527.4M$0.61$0.60 – $0.635

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.93%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+22.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+58.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 66.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.025-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 18Campbell RogersChief Medical Officer19.7K sh$987KSellSep 18Vikram VergheseCFO16.8K sh$851KSellSep 17Vikram VergheseCFO7.6K sh$380KSellSep 15Vikram VergheseCFO668 sh$33KSellSep 14Vikram VergheseCFO4.6K sh$231KSellSep 11Vikram VergheseCFO29.7K sh$1.5MSellSep 11Farquhar John C.m.CEO3.9K sh$195KSellSep 10Farquhar John C.m.CEO35.0K sh$1.6MSellSep 8Vikram VergheseCFO6.6K sh$332KSellSep 3Vikram VergheseCFO27.5K sh$1.4M
1–10 of 22
+ 27 other (12 exempts · 9 inkinds · 6 awards) in window

See when $HTFL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
+ 13 other (6 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Vikram Verghese Sells 7,579 Shares of Heartflow (NASDAQ:HTFL) Stockdefenseworld.net·10d agoHeartflow (NASDAQ:HTFL) Reaches New 52-Week High – Still a Buy?defenseworld.net·10d ago12,278 Shares in Heartflow, Inc. $HTFL Bought by Amundidefenseworld.net·12d agoJohn C.M. Farquhar Sells 35,010 Shares of Heartflow (NASDAQ:HTFL) Stockdefenseworld.net·14d agoHeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week Highfool.com·15d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$HCAT$DOCS$TDOC$SOPH$HNGE$BTSG$OPRX
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport